Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Experimental arthritis

Outcome of Btk blockade in mice

Nature Reviews Rheumatology volume 7, page 497 (2011)Cite this article

Subjects

The Bruton tyrosine kinase (Btk) inhibitor PCI-32765—currently in clinical development as a potential treatment for B-cell lymphomas—shows therapeutic promise in mouse models of inflammatory arthritis, according to a paper now published in Arthritis Research & Therapy.

The research was conducted by Betty Chang and colleagues at Pharmacyclics Inc., a company that is actively involved in the commercialization of Btk inhibitors. First, the team assessed the in vivo effects of PCI-32765 in animal models of arthritis, and then they investigated how the drug might work.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

ORIGINAL RESEARCH PAPER

  1. Chang, B. Y. et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res. Ther. 13, R115 (2011)

    Article  CAS  Google Scholar 

Download references

Authors
  1. Jenny Buckland
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buckland, J. Outcome of Btk blockade in mice. Nat Rev Rheumatol 7, 497 (2011). https://doi.org/10.1038/nrrheum.2011.118

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrrheum.2011.118

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing